Pazopanib: 7 agencies, 2010–2019
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Treatment of adult patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy…”, while SMC (Scotland) recorded not recommended for “For the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have …”.
Assessment has run over 9.6 years, from 1 Mar 2010 at AWMSG (Wales) to 23 Oct 2019 at HAS (France).
SMC (Scotland) changed its position: restricted on 7 Mar 2011, not recommended by 10 Dec 2012.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2019; on this evidence the file is dormant.
5 distinct indication wordings are recorded for pazopanib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess pazopanib, on 1 Mar 2010; HAS (France) did not open a file until 9 Jan 2013 — a moderate spread of 2.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 2 of 8 decisive outcomes narrowed pazopanib to a subgroup rather than accepting or refusing it outright, at PHARMAC (New Zealand) and SMC (Scotland).
4 of the 7 agencies here assessed pazopanib more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for pazopanib.
The full ledger for pazopanib reads 4 recommended, 4 other, 2 not recommended and 2 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 23 Oct 2019 | Listing renewal (Transparency Committee) | SMR substantial | source |
| PHARMAC (New Zealand) | 9 Nov 2017 | Advanced soft tissue sarcoma after prior chemotherapy | PTAC advice: Decline · decision reached | source |
| SMC (Scotland) | 7 Mar 2011 | For the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease | accepted (restricted) | source |
| NICE (England) | 23 Feb 2011 | NICE TA215 | recommended | source |
| AWMSG (Wales) | 18 Jun 2010 | Treatment of advanced renal cell carcinoma for patients who have received prior cytokine therapy for advanced disease | outside AWMSG criteria | source |
9 further decisions for pazopanib, across 6 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- cabozantinib — divergent outcome (recommended vs not recommended) on a shared indication
- tivozanib — divergent outcome (recommended vs restricted) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
Coverage: 14 decisions for pazopanib from 7 agencies, 2010 to 2019. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.